Should you buy aTyr Pharma stock? (NasdaqGS:LIFE). Let's see how it does in our automated value investing analysis system.
(aTyr Pharma stock price per share)
||LIFE Fair Price
(based on intrinsic value)
|LIFE Safety Price (based on a variable margin of safety)||$-15.10|
|PE Ratio versus Sector||38% higher than other Healthcare stocks|
|PE Ratio versus Industry||51% lower than other Biotechnology stocks|
|Free Cash Flow Jitter||24%|
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 546,540 shares shorted. With 13,738,767 shares available for purchase and an average trading volume over the past 10 trading days of 448,962, it would take at least 1.217 days for all of the short holders to cover their shorts.
We believe that aTyr Pharma may be worth examining further. It's making money, which is a very positive sign. Is it on sale?
aTyr Pharma looks overpriced right now. If you're looking for a bargain in the stock market, you should probably look elsewhere for a great deal. This might still be a great stock to own—but it's not on sale right now.
Does aTyr Pharma have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
Most Popular Articles